Edema Clinical Comprehensive Study by Type (Systematic Edema Clinical {Cardiac Disease, Hepatic Disease, Renal Disease, Others}, Local Edema Clinical {Cellulitis, Chronic Venous Insufficiency, Others}), Application (Hospital, Clinical Research Organization, Other), Edema (Peripheral Edema, Pedal Edema, Lymphedema, Pulmonary Edema, Others), Tests (Ultrasonography, Lymphoscintigraphy, Magnetic Resonance Imaging, Others) Players and Region - Global Market Outlook to 2026

Edema Clinical Market by XX Submarkets | Forecast Years 2022-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
The edema clinical is the tests and clinical trials for the disease called edema which is the medical term for the swelling in the body. Edema happens when the small blood vessels rupture and leaks fluid into nearby tissues, because of which extra fluid builds up making the tissue swell, it can happen in any part of the body. It can be caused by any kind of injury or inflammation.This growth is primarily driven by The increasing need for research trials in various types of diseases, causes, and possible treatment. It helps determine the intensity of specific disease or disorder helping in drug discovery along with observing its applications and impact on the disease.

Globally, a noticeable market trend is evident The Rising Enrolment of Patients in Edema Clinical . Major Players, such as Roche AG (Switzerland), GlaxoSmithKline plc (United Kingdom), Boehringer Sohn AG & Ko. KG (Germany), CMP Pharma (United States), Otsuka Holdings Co Ltd (Japan), Endo International plc (Ireland), Syneos Health (United States), KalVista Pharmaceuticals, Inc. (United States) and Opthea Limited (Canada) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On 7th January 2020, Opthea Limited announced the completion of its patient recruitment in the company for Phase 2 a trial evaluating the safety and efficacy of OPT-302 administered in combination with aflibercept (Eylea) for treatment of diabetic macular edema (DME).
On 10th Feb 2020, KalVista Pharmaceuticals, Inc is a clinical-stage pharmaceutical company focused on developing and discovering of small molecule protease inhibitors. The company announced the agreement with Merck related to intravitreal diabetic macular edema candidate KVD001 and future oral DME molecules has expired.

Market Drivers
  • The increasing need for research trials in various types of diseases, causes, and possible treatment. It helps determine the intensity of specific disease or disorder helping in drug discovery along with observing its applications and impact on the disease

Market Trend
  • The Rising Enrolment of Patients in Edema Clinical
  • Introduction of Artificial Intelligence in Edema Clinical

Restraints
  • Risk of Side Effects of Edema Clinical on Patients Might be the Hindrance for the Market

Opportunities
Rising Fundings on Clinical Research Industry will Boost the Edema Clinical Market
Challenges
Adherence to Regulatory Guidelines

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Edema Clinical Study Sheds Light on
— The Edema Clinical Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Edema Clinical industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Edema Clinical industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Systematic Edema Clinical {Cardiac Disease, Hepatic Disease, Renal Disease, Others}
  • Local Edema Clinical {Cellulitis, Chronic Venous Insufficiency, Others}
By Application
  • Hospital
  • Clinical Research Organization
  • Other
By Edema
  • Peripheral Edema
  • Pedal Edema
  • Lymphedema
  • Pulmonary Edema
  • Others

By Tests
  • Ultrasonography
  • Lymphoscintigraphy
  • Magnetic Resonance Imaging
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The increasing need for research trials in various types of diseases, causes, and possible treatment. It helps determine the intensity of specific disease or disorder helping in drug discovery along with observing its applications and impact on the disease
    • 3.3. Market Challenges
      • 3.3.1. Adherence to Regulatory Guidelines
    • 3.4. Market Trends
      • 3.4.1. The Rising Enrolment of Patients in Edema Clinical
      • 3.4.2. Introduction of Artificial Intelligence in Edema Clinical
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Edema Clinical, by Type, Application, Edema, Tests and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Edema Clinical (Value)
      • 5.2.1. Global Edema Clinical by: Type (Value)
        • 5.2.1.1. Systematic Edema Clinical {Cardiac Disease, Hepatic Disease, Renal Disease, Others}
        • 5.2.1.2. Local Edema Clinical {Cellulitis, Chronic Venous Insufficiency, Others}
      • 5.2.2. Global Edema Clinical by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinical Research Organization
        • 5.2.2.3. Other
      • 5.2.3. Global Edema Clinical by: Edema (Value)
        • 5.2.3.1. Peripheral Edema
        • 5.2.3.2. Pedal Edema
        • 5.2.3.3. Lymphedema
        • 5.2.3.4. Pulmonary Edema
        • 5.2.3.5. Others
      • 5.2.4. Global Edema Clinical by: Tests (Value)
        • 5.2.4.1. Ultrasonography
        • 5.2.4.2. Lymphoscintigraphy
        • 5.2.4.3. Magnetic Resonance Imaging
        • 5.2.4.4. Others
      • 5.2.5. Global Edema Clinical Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Edema Clinical: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Roche AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline plc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Boehringer Sohn AG & Ko. KG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. CMP Pharma (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Otsuka Holdings Co Ltd (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Endo International plc (Ireland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Syneos Health (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. KalVista Pharmaceuticals, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Opthea Limited (Canada)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Edema Clinical Sale, by Type, Application, Edema, Tests and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Edema Clinical (Value)
      • 7.2.1. Global Edema Clinical by: Type (Value)
        • 7.2.1.1. Systematic Edema Clinical {Cardiac Disease, Hepatic Disease, Renal Disease, Others}
        • 7.2.1.2. Local Edema Clinical {Cellulitis, Chronic Venous Insufficiency, Others}
      • 7.2.2. Global Edema Clinical by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinical Research Organization
        • 7.2.2.3. Other
      • 7.2.3. Global Edema Clinical by: Edema (Value)
        • 7.2.3.1. Peripheral Edema
        • 7.2.3.2. Pedal Edema
        • 7.2.3.3. Lymphedema
        • 7.2.3.4. Pulmonary Edema
        • 7.2.3.5. Others
      • 7.2.4. Global Edema Clinical by: Tests (Value)
        • 7.2.4.1. Ultrasonography
        • 7.2.4.2. Lymphoscintigraphy
        • 7.2.4.3. Magnetic Resonance Imaging
        • 7.2.4.4. Others
      • 7.2.5. Global Edema Clinical Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Edema Clinical: by Type(USD Million)
  • Table 2. Edema Clinical Systematic Edema Clinical {Cardiac Disease, Hepatic Disease, Renal Disease, Others} , by Region USD Million (2015-2020)
  • Table 3. Edema Clinical Local Edema Clinical {Cellulitis, Chronic Venous Insufficiency, Others} , by Region USD Million (2015-2020)
  • Table 4. Edema Clinical: by Application(USD Million)
  • Table 5. Edema Clinical Hospital , by Region USD Million (2015-2020)
  • Table 6. Edema Clinical Clinical Research Organization , by Region USD Million (2015-2020)
  • Table 7. Edema Clinical Other , by Region USD Million (2015-2020)
  • Table 8. Edema Clinical: by Edema(USD Million)
  • Table 9. Edema Clinical Peripheral Edema , by Region USD Million (2015-2020)
  • Table 10. Edema Clinical Pedal Edema , by Region USD Million (2015-2020)
  • Table 11. Edema Clinical Lymphedema , by Region USD Million (2015-2020)
  • Table 12. Edema Clinical Pulmonary Edema , by Region USD Million (2015-2020)
  • Table 13. Edema Clinical Others , by Region USD Million (2015-2020)
  • Table 14. Edema Clinical: by Tests(USD Million)
  • Table 15. Edema Clinical Ultrasonography , by Region USD Million (2015-2020)
  • Table 16. Edema Clinical Lymphoscintigraphy , by Region USD Million (2015-2020)
  • Table 17. Edema Clinical Magnetic Resonance Imaging , by Region USD Million (2015-2020)
  • Table 18. Edema Clinical Others , by Region USD Million (2015-2020)
  • Table 19. South America Edema Clinical, by Country USD Million (2015-2020)
  • Table 20. South America Edema Clinical, by Type USD Million (2015-2020)
  • Table 21. South America Edema Clinical, by Application USD Million (2015-2020)
  • Table 22. South America Edema Clinical, by Edema USD Million (2015-2020)
  • Table 23. South America Edema Clinical, by Tests USD Million (2015-2020)
  • Table 24. Brazil Edema Clinical, by Type USD Million (2015-2020)
  • Table 25. Brazil Edema Clinical, by Application USD Million (2015-2020)
  • Table 26. Brazil Edema Clinical, by Edema USD Million (2015-2020)
  • Table 27. Brazil Edema Clinical, by Tests USD Million (2015-2020)
  • Table 28. Argentina Edema Clinical, by Type USD Million (2015-2020)
  • Table 29. Argentina Edema Clinical, by Application USD Million (2015-2020)
  • Table 30. Argentina Edema Clinical, by Edema USD Million (2015-2020)
  • Table 31. Argentina Edema Clinical, by Tests USD Million (2015-2020)
  • Table 32. Rest of South America Edema Clinical, by Type USD Million (2015-2020)
  • Table 33. Rest of South America Edema Clinical, by Application USD Million (2015-2020)
  • Table 34. Rest of South America Edema Clinical, by Edema USD Million (2015-2020)
  • Table 35. Rest of South America Edema Clinical, by Tests USD Million (2015-2020)
  • Table 36. Asia Pacific Edema Clinical, by Country USD Million (2015-2020)
  • Table 37. Asia Pacific Edema Clinical, by Type USD Million (2015-2020)
  • Table 38. Asia Pacific Edema Clinical, by Application USD Million (2015-2020)
  • Table 39. Asia Pacific Edema Clinical, by Edema USD Million (2015-2020)
  • Table 40. Asia Pacific Edema Clinical, by Tests USD Million (2015-2020)
  • Table 41. China Edema Clinical, by Type USD Million (2015-2020)
  • Table 42. China Edema Clinical, by Application USD Million (2015-2020)
  • Table 43. China Edema Clinical, by Edema USD Million (2015-2020)
  • Table 44. China Edema Clinical, by Tests USD Million (2015-2020)
  • Table 45. Japan Edema Clinical, by Type USD Million (2015-2020)
  • Table 46. Japan Edema Clinical, by Application USD Million (2015-2020)
  • Table 47. Japan Edema Clinical, by Edema USD Million (2015-2020)
  • Table 48. Japan Edema Clinical, by Tests USD Million (2015-2020)
  • Table 49. India Edema Clinical, by Type USD Million (2015-2020)
  • Table 50. India Edema Clinical, by Application USD Million (2015-2020)
  • Table 51. India Edema Clinical, by Edema USD Million (2015-2020)
  • Table 52. India Edema Clinical, by Tests USD Million (2015-2020)
  • Table 53. South Korea Edema Clinical, by Type USD Million (2015-2020)
  • Table 54. South Korea Edema Clinical, by Application USD Million (2015-2020)
  • Table 55. South Korea Edema Clinical, by Edema USD Million (2015-2020)
  • Table 56. South Korea Edema Clinical, by Tests USD Million (2015-2020)
  • Table 57. Taiwan Edema Clinical, by Type USD Million (2015-2020)
  • Table 58. Taiwan Edema Clinical, by Application USD Million (2015-2020)
  • Table 59. Taiwan Edema Clinical, by Edema USD Million (2015-2020)
  • Table 60. Taiwan Edema Clinical, by Tests USD Million (2015-2020)
  • Table 61. Australia Edema Clinical, by Type USD Million (2015-2020)
  • Table 62. Australia Edema Clinical, by Application USD Million (2015-2020)
  • Table 63. Australia Edema Clinical, by Edema USD Million (2015-2020)
  • Table 64. Australia Edema Clinical, by Tests USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Edema Clinical, by Type USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Edema Clinical, by Application USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Edema Clinical, by Edema USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Edema Clinical, by Tests USD Million (2015-2020)
  • Table 69. Europe Edema Clinical, by Country USD Million (2015-2020)
  • Table 70. Europe Edema Clinical, by Type USD Million (2015-2020)
  • Table 71. Europe Edema Clinical, by Application USD Million (2015-2020)
  • Table 72. Europe Edema Clinical, by Edema USD Million (2015-2020)
  • Table 73. Europe Edema Clinical, by Tests USD Million (2015-2020)
  • Table 74. Germany Edema Clinical, by Type USD Million (2015-2020)
  • Table 75. Germany Edema Clinical, by Application USD Million (2015-2020)
  • Table 76. Germany Edema Clinical, by Edema USD Million (2015-2020)
  • Table 77. Germany Edema Clinical, by Tests USD Million (2015-2020)
  • Table 78. France Edema Clinical, by Type USD Million (2015-2020)
  • Table 79. France Edema Clinical, by Application USD Million (2015-2020)
  • Table 80. France Edema Clinical, by Edema USD Million (2015-2020)
  • Table 81. France Edema Clinical, by Tests USD Million (2015-2020)
  • Table 82. Italy Edema Clinical, by Type USD Million (2015-2020)
  • Table 83. Italy Edema Clinical, by Application USD Million (2015-2020)
  • Table 84. Italy Edema Clinical, by Edema USD Million (2015-2020)
  • Table 85. Italy Edema Clinical, by Tests USD Million (2015-2020)
  • Table 86. United Kingdom Edema Clinical, by Type USD Million (2015-2020)
  • Table 87. United Kingdom Edema Clinical, by Application USD Million (2015-2020)
  • Table 88. United Kingdom Edema Clinical, by Edema USD Million (2015-2020)
  • Table 89. United Kingdom Edema Clinical, by Tests USD Million (2015-2020)
  • Table 90. Netherlands Edema Clinical, by Type USD Million (2015-2020)
  • Table 91. Netherlands Edema Clinical, by Application USD Million (2015-2020)
  • Table 92. Netherlands Edema Clinical, by Edema USD Million (2015-2020)
  • Table 93. Netherlands Edema Clinical, by Tests USD Million (2015-2020)
  • Table 94. Rest of Europe Edema Clinical, by Type USD Million (2015-2020)
  • Table 95. Rest of Europe Edema Clinical, by Application USD Million (2015-2020)
  • Table 96. Rest of Europe Edema Clinical, by Edema USD Million (2015-2020)
  • Table 97. Rest of Europe Edema Clinical, by Tests USD Million (2015-2020)
  • Table 98. MEA Edema Clinical, by Country USD Million (2015-2020)
  • Table 99. MEA Edema Clinical, by Type USD Million (2015-2020)
  • Table 100. MEA Edema Clinical, by Application USD Million (2015-2020)
  • Table 101. MEA Edema Clinical, by Edema USD Million (2015-2020)
  • Table 102. MEA Edema Clinical, by Tests USD Million (2015-2020)
  • Table 103. Middle East Edema Clinical, by Type USD Million (2015-2020)
  • Table 104. Middle East Edema Clinical, by Application USD Million (2015-2020)
  • Table 105. Middle East Edema Clinical, by Edema USD Million (2015-2020)
  • Table 106. Middle East Edema Clinical, by Tests USD Million (2015-2020)
  • Table 107. Africa Edema Clinical, by Type USD Million (2015-2020)
  • Table 108. Africa Edema Clinical, by Application USD Million (2015-2020)
  • Table 109. Africa Edema Clinical, by Edema USD Million (2015-2020)
  • Table 110. Africa Edema Clinical, by Tests USD Million (2015-2020)
  • Table 111. North America Edema Clinical, by Country USD Million (2015-2020)
  • Table 112. North America Edema Clinical, by Type USD Million (2015-2020)
  • Table 113. North America Edema Clinical, by Application USD Million (2015-2020)
  • Table 114. North America Edema Clinical, by Edema USD Million (2015-2020)
  • Table 115. North America Edema Clinical, by Tests USD Million (2015-2020)
  • Table 116. United States Edema Clinical, by Type USD Million (2015-2020)
  • Table 117. United States Edema Clinical, by Application USD Million (2015-2020)
  • Table 118. United States Edema Clinical, by Edema USD Million (2015-2020)
  • Table 119. United States Edema Clinical, by Tests USD Million (2015-2020)
  • Table 120. Canada Edema Clinical, by Type USD Million (2015-2020)
  • Table 121. Canada Edema Clinical, by Application USD Million (2015-2020)
  • Table 122. Canada Edema Clinical, by Edema USD Million (2015-2020)
  • Table 123. Canada Edema Clinical, by Tests USD Million (2015-2020)
  • Table 124. Mexico Edema Clinical, by Type USD Million (2015-2020)
  • Table 125. Mexico Edema Clinical, by Application USD Million (2015-2020)
  • Table 126. Mexico Edema Clinical, by Edema USD Million (2015-2020)
  • Table 127. Mexico Edema Clinical, by Tests USD Million (2015-2020)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Edema Clinical: by Type(USD Million)
  • Table 138. Edema Clinical Systematic Edema Clinical {Cardiac Disease, Hepatic Disease, Renal Disease, Others} , by Region USD Million (2021-2026)
  • Table 139. Edema Clinical Local Edema Clinical {Cellulitis, Chronic Venous Insufficiency, Others} , by Region USD Million (2021-2026)
  • Table 140. Edema Clinical: by Application(USD Million)
  • Table 141. Edema Clinical Hospital , by Region USD Million (2021-2026)
  • Table 142. Edema Clinical Clinical Research Organization , by Region USD Million (2021-2026)
  • Table 143. Edema Clinical Other , by Region USD Million (2021-2026)
  • Table 144. Edema Clinical: by Edema(USD Million)
  • Table 145. Edema Clinical Peripheral Edema , by Region USD Million (2021-2026)
  • Table 146. Edema Clinical Pedal Edema , by Region USD Million (2021-2026)
  • Table 147. Edema Clinical Lymphedema , by Region USD Million (2021-2026)
  • Table 148. Edema Clinical Pulmonary Edema , by Region USD Million (2021-2026)
  • Table 149. Edema Clinical Others , by Region USD Million (2021-2026)
  • Table 150. Edema Clinical: by Tests(USD Million)
  • Table 151. Edema Clinical Ultrasonography , by Region USD Million (2021-2026)
  • Table 152. Edema Clinical Lymphoscintigraphy , by Region USD Million (2021-2026)
  • Table 153. Edema Clinical Magnetic Resonance Imaging , by Region USD Million (2021-2026)
  • Table 154. Edema Clinical Others , by Region USD Million (2021-2026)
  • Table 155. South America Edema Clinical, by Country USD Million (2021-2026)
  • Table 156. South America Edema Clinical, by Type USD Million (2021-2026)
  • Table 157. South America Edema Clinical, by Application USD Million (2021-2026)
  • Table 158. South America Edema Clinical, by Edema USD Million (2021-2026)
  • Table 159. South America Edema Clinical, by Tests USD Million (2021-2026)
  • Table 160. Brazil Edema Clinical, by Type USD Million (2021-2026)
  • Table 161. Brazil Edema Clinical, by Application USD Million (2021-2026)
  • Table 162. Brazil Edema Clinical, by Edema USD Million (2021-2026)
  • Table 163. Brazil Edema Clinical, by Tests USD Million (2021-2026)
  • Table 164. Argentina Edema Clinical, by Type USD Million (2021-2026)
  • Table 165. Argentina Edema Clinical, by Application USD Million (2021-2026)
  • Table 166. Argentina Edema Clinical, by Edema USD Million (2021-2026)
  • Table 167. Argentina Edema Clinical, by Tests USD Million (2021-2026)
  • Table 168. Rest of South America Edema Clinical, by Type USD Million (2021-2026)
  • Table 169. Rest of South America Edema Clinical, by Application USD Million (2021-2026)
  • Table 170. Rest of South America Edema Clinical, by Edema USD Million (2021-2026)
  • Table 171. Rest of South America Edema Clinical, by Tests USD Million (2021-2026)
  • Table 172. Asia Pacific Edema Clinical, by Country USD Million (2021-2026)
  • Table 173. Asia Pacific Edema Clinical, by Type USD Million (2021-2026)
  • Table 174. Asia Pacific Edema Clinical, by Application USD Million (2021-2026)
  • Table 175. Asia Pacific Edema Clinical, by Edema USD Million (2021-2026)
  • Table 176. Asia Pacific Edema Clinical, by Tests USD Million (2021-2026)
  • Table 177. China Edema Clinical, by Type USD Million (2021-2026)
  • Table 178. China Edema Clinical, by Application USD Million (2021-2026)
  • Table 179. China Edema Clinical, by Edema USD Million (2021-2026)
  • Table 180. China Edema Clinical, by Tests USD Million (2021-2026)
  • Table 181. Japan Edema Clinical, by Type USD Million (2021-2026)
  • Table 182. Japan Edema Clinical, by Application USD Million (2021-2026)
  • Table 183. Japan Edema Clinical, by Edema USD Million (2021-2026)
  • Table 184. Japan Edema Clinical, by Tests USD Million (2021-2026)
  • Table 185. India Edema Clinical, by Type USD Million (2021-2026)
  • Table 186. India Edema Clinical, by Application USD Million (2021-2026)
  • Table 187. India Edema Clinical, by Edema USD Million (2021-2026)
  • Table 188. India Edema Clinical, by Tests USD Million (2021-2026)
  • Table 189. South Korea Edema Clinical, by Type USD Million (2021-2026)
  • Table 190. South Korea Edema Clinical, by Application USD Million (2021-2026)
  • Table 191. South Korea Edema Clinical, by Edema USD Million (2021-2026)
  • Table 192. South Korea Edema Clinical, by Tests USD Million (2021-2026)
  • Table 193. Taiwan Edema Clinical, by Type USD Million (2021-2026)
  • Table 194. Taiwan Edema Clinical, by Application USD Million (2021-2026)
  • Table 195. Taiwan Edema Clinical, by Edema USD Million (2021-2026)
  • Table 196. Taiwan Edema Clinical, by Tests USD Million (2021-2026)
  • Table 197. Australia Edema Clinical, by Type USD Million (2021-2026)
  • Table 198. Australia Edema Clinical, by Application USD Million (2021-2026)
  • Table 199. Australia Edema Clinical, by Edema USD Million (2021-2026)
  • Table 200. Australia Edema Clinical, by Tests USD Million (2021-2026)
  • Table 201. Rest of Asia-Pacific Edema Clinical, by Type USD Million (2021-2026)
  • Table 202. Rest of Asia-Pacific Edema Clinical, by Application USD Million (2021-2026)
  • Table 203. Rest of Asia-Pacific Edema Clinical, by Edema USD Million (2021-2026)
  • Table 204. Rest of Asia-Pacific Edema Clinical, by Tests USD Million (2021-2026)
  • Table 205. Europe Edema Clinical, by Country USD Million (2021-2026)
  • Table 206. Europe Edema Clinical, by Type USD Million (2021-2026)
  • Table 207. Europe Edema Clinical, by Application USD Million (2021-2026)
  • Table 208. Europe Edema Clinical, by Edema USD Million (2021-2026)
  • Table 209. Europe Edema Clinical, by Tests USD Million (2021-2026)
  • Table 210. Germany Edema Clinical, by Type USD Million (2021-2026)
  • Table 211. Germany Edema Clinical, by Application USD Million (2021-2026)
  • Table 212. Germany Edema Clinical, by Edema USD Million (2021-2026)
  • Table 213. Germany Edema Clinical, by Tests USD Million (2021-2026)
  • Table 214. France Edema Clinical, by Type USD Million (2021-2026)
  • Table 215. France Edema Clinical, by Application USD Million (2021-2026)
  • Table 216. France Edema Clinical, by Edema USD Million (2021-2026)
  • Table 217. France Edema Clinical, by Tests USD Million (2021-2026)
  • Table 218. Italy Edema Clinical, by Type USD Million (2021-2026)
  • Table 219. Italy Edema Clinical, by Application USD Million (2021-2026)
  • Table 220. Italy Edema Clinical, by Edema USD Million (2021-2026)
  • Table 221. Italy Edema Clinical, by Tests USD Million (2021-2026)
  • Table 222. United Kingdom Edema Clinical, by Type USD Million (2021-2026)
  • Table 223. United Kingdom Edema Clinical, by Application USD Million (2021-2026)
  • Table 224. United Kingdom Edema Clinical, by Edema USD Million (2021-2026)
  • Table 225. United Kingdom Edema Clinical, by Tests USD Million (2021-2026)
  • Table 226. Netherlands Edema Clinical, by Type USD Million (2021-2026)
  • Table 227. Netherlands Edema Clinical, by Application USD Million (2021-2026)
  • Table 228. Netherlands Edema Clinical, by Edema USD Million (2021-2026)
  • Table 229. Netherlands Edema Clinical, by Tests USD Million (2021-2026)
  • Table 230. Rest of Europe Edema Clinical, by Type USD Million (2021-2026)
  • Table 231. Rest of Europe Edema Clinical, by Application USD Million (2021-2026)
  • Table 232. Rest of Europe Edema Clinical, by Edema USD Million (2021-2026)
  • Table 233. Rest of Europe Edema Clinical, by Tests USD Million (2021-2026)
  • Table 234. MEA Edema Clinical, by Country USD Million (2021-2026)
  • Table 235. MEA Edema Clinical, by Type USD Million (2021-2026)
  • Table 236. MEA Edema Clinical, by Application USD Million (2021-2026)
  • Table 237. MEA Edema Clinical, by Edema USD Million (2021-2026)
  • Table 238. MEA Edema Clinical, by Tests USD Million (2021-2026)
  • Table 239. Middle East Edema Clinical, by Type USD Million (2021-2026)
  • Table 240. Middle East Edema Clinical, by Application USD Million (2021-2026)
  • Table 241. Middle East Edema Clinical, by Edema USD Million (2021-2026)
  • Table 242. Middle East Edema Clinical, by Tests USD Million (2021-2026)
  • Table 243. Africa Edema Clinical, by Type USD Million (2021-2026)
  • Table 244. Africa Edema Clinical, by Application USD Million (2021-2026)
  • Table 245. Africa Edema Clinical, by Edema USD Million (2021-2026)
  • Table 246. Africa Edema Clinical, by Tests USD Million (2021-2026)
  • Table 247. North America Edema Clinical, by Country USD Million (2021-2026)
  • Table 248. North America Edema Clinical, by Type USD Million (2021-2026)
  • Table 249. North America Edema Clinical, by Application USD Million (2021-2026)
  • Table 250. North America Edema Clinical, by Edema USD Million (2021-2026)
  • Table 251. North America Edema Clinical, by Tests USD Million (2021-2026)
  • Table 252. United States Edema Clinical, by Type USD Million (2021-2026)
  • Table 253. United States Edema Clinical, by Application USD Million (2021-2026)
  • Table 254. United States Edema Clinical, by Edema USD Million (2021-2026)
  • Table 255. United States Edema Clinical, by Tests USD Million (2021-2026)
  • Table 256. Canada Edema Clinical, by Type USD Million (2021-2026)
  • Table 257. Canada Edema Clinical, by Application USD Million (2021-2026)
  • Table 258. Canada Edema Clinical, by Edema USD Million (2021-2026)
  • Table 259. Canada Edema Clinical, by Tests USD Million (2021-2026)
  • Table 260. Mexico Edema Clinical, by Type USD Million (2021-2026)
  • Table 261. Mexico Edema Clinical, by Application USD Million (2021-2026)
  • Table 262. Mexico Edema Clinical, by Edema USD Million (2021-2026)
  • Table 263. Mexico Edema Clinical, by Tests USD Million (2021-2026)
  • Table 264. Research Programs/Design for This Report
  • Table 265. Key Data Information from Secondary Sources
  • Table 266. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Edema Clinical: by Type USD Million (2015-2020)
  • Figure 5. Global Edema Clinical: by Application USD Million (2015-2020)
  • Figure 6. Global Edema Clinical: by Edema USD Million (2015-2020)
  • Figure 7. Global Edema Clinical: by Tests USD Million (2015-2020)
  • Figure 8. South America Edema Clinical Share (%), by Country
  • Figure 9. Asia Pacific Edema Clinical Share (%), by Country
  • Figure 10. Europe Edema Clinical Share (%), by Country
  • Figure 11. MEA Edema Clinical Share (%), by Country
  • Figure 12. North America Edema Clinical Share (%), by Country
  • Figure 13. Global Edema Clinical share by Players 2020 (%)
  • Figure 14. Global Edema Clinical share by Players (Top 3) 2020(%)
  • Figure 15. Global Edema Clinical share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Roche AG (Switzerland) Revenue: by Geography 2020
  • Figure 19. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 21. Boehringer Sohn AG & Ko. KG (Germany) Revenue, Net Income and Gross profit
  • Figure 22. Boehringer Sohn AG & Ko. KG (Germany) Revenue: by Geography 2020
  • Figure 23. CMP Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 24. CMP Pharma (United States) Revenue: by Geography 2020
  • Figure 25. Otsuka Holdings Co Ltd (Japan) Revenue, Net Income and Gross profit
  • Figure 26. Otsuka Holdings Co Ltd (Japan) Revenue: by Geography 2020
  • Figure 27. Endo International plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 28. Endo International plc (Ireland) Revenue: by Geography 2020
  • Figure 29. Syneos Health (United States) Revenue, Net Income and Gross profit
  • Figure 30. Syneos Health (United States) Revenue: by Geography 2020
  • Figure 31. KalVista Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. KalVista Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 33. Opthea Limited (Canada) Revenue, Net Income and Gross profit
  • Figure 34. Opthea Limited (Canada) Revenue: by Geography 2020
  • Figure 35. Global Edema Clinical: by Type USD Million (2021-2026)
  • Figure 36. Global Edema Clinical: by Application USD Million (2021-2026)
  • Figure 37. Global Edema Clinical: by Edema USD Million (2021-2026)
  • Figure 38. Global Edema Clinical: by Tests USD Million (2021-2026)
  • Figure 39. South America Edema Clinical Share (%), by Country
  • Figure 40. Asia Pacific Edema Clinical Share (%), by Country
  • Figure 41. Europe Edema Clinical Share (%), by Country
  • Figure 42. MEA Edema Clinical Share (%), by Country
  • Figure 43. North America Edema Clinical Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Roche AG (Switzerland)
  • GlaxoSmithKline plc (United Kingdom)
  • Boehringer Sohn AG & Ko. KG (Germany)
  • CMP Pharma (United States)
  • Otsuka Holdings Co Ltd (Japan)
  • Endo International plc (Ireland)
  • Syneos Health (United States)
  • KalVista Pharmaceuticals, Inc. (United States)
  • Opthea Limited (Canada)
Select User Access Type

Key Highlights of Report


Sep 2021 210 Pages 70 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026
Companies that are profiled in Global Edema Clinical Market are Roche AG (Switzerland), GlaxoSmithKline plc (United Kingdom), Boehringer Sohn AG & Ko. KG (Germany), CMP Pharma (United States), Otsuka Holdings Co Ltd (Japan), Endo International plc (Ireland), Syneos Health (United States), KalVista Pharmaceuticals, Inc. (United States) and Opthea Limited (Canada) etc.
The edema clinical is the tests and clinical trials for the disease called edema which is the medical term for the swelling in the body. Edema happens when the small blood vessels rupture and leaks fluid into nearby tissues, because of which extra fluid builds up making the tissue swell, it can happen in any part of the body. It can be caused by any kind of injury or inflammation.

Know More About Global Edema Clinical Market Report?